The State of Weight Loss Drugs – The Motley Fool

The State of Weight Loss Drugs  The Motley Fool

The State of Weight Loss Drugs – The Motley Fool

The State of Weight Loss Drugs  The Motley Fool

Novo’s Wegovy successor disappoints in second large trial – BioPharma Dive

Novo’s Wegovy successor disappoints in second large trial  BioPharma Dive

Novo Nordisk shares fall on weight-loss drug trial – MSN

Novo Nordisk shares fall on weight-loss drug trial  MSN

Sugar reduction and GLP-1s – Food Business News

Sugar reduction and GLP-1s  Food Business News

Novo Nordisk shares fall on weight-loss drug trial – Fox Business

Novo Nordisk shares fall on weight-loss drug trial  Fox Business

IA-2A positivity identified as a key predictor in type 1 diabetes progression

A recent study published in Diabetologia has identified insulinoma-associated protein 2 autoantibody (IA-2A) positivity as a…

Novo Nordisk shares fall on weight loss drug trial results – Proactive Investors USA

Novo Nordisk shares fall on weight loss drug trial results  Proactive Investors USA

Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain. – Barron’s

Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.  Barron’s

Roche announces hub for cardiovascular, renal and metabolism research

Roche has announced the launch of the Roche Genentech Innovation Center Boston, which will serve as…